ReviewFrontiers in medicine2025
Machine learning in lupus nephritis: bridging prediction models and clinical decision-making towards personalized nephrology.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The application of artificial intelligence in systemic lupus erythematosus: a bibliometric analysis of current trends and future directions.Frontiers in medicine · 2026Pooled it
- Artificial intelligence in membranous nephropathy: transforming clinical management toward precision medicine.Frontiers in medicine · 2026Review
- Applications of artificial intelligence in systemic lupus erythematosus: integrating multi-omics data for precision medicine.Frontiers in immunology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), affecting up to 65% of patients and contributing significantly to morbidity and mortality. The heterogeneous clinical course of LN-characterized by alternating flares and remissions-stems from complex immunological, genetic, endocrine, and environmental factors. Current management strategies rely on immunosuppressants and corticosteroids, yet predicting disease progression, treatment response, and relapse risk remains challenging. Objective: This review synthesizes current evidence on the use of machine learning (ML) models for predicting, diagnosing, and monitoring LN, emphasizing their translational potential to improve clinical decision-making and enable personalized nephrology. Methods: A narrative synthesis was conducted of studies published between 2015 and April 2024, identified through PubMed using the terms ("lupus nephritis" OR "LN") AND ("machine learning" OR "artificial intelligence" OR "deep learning"). Eligible studies included those applying ML models to LN for diagnosis, histological classification, flare prediction, treatment response, or prognosis. Results: We identified diverse ML approaches-including logistic regression, decision trees, random forests, support vector machines, neural networks, gradient boosting, and clustering-applied to multimodal data sources (clinical, laboratory, imaging, histopathology, and omics). These models demonstrated high performance in tasks such as non-invasive histology classification (AUC up to 0.98), flare prediction, and individualized risk stratification. Integration with big data frameworks enhanced the identification of molecular drivers, improved prognostic accuracy, and facilitated remote patient monitoring. However, model development in LN remains limited by small datasets, lack of external validation, and heterogeneous outcome definitions. Conclusion: ML models have the potential to transform LN management by enabling earlier flare detection, personalized treatment strategies, and non-invasive disease monitoring. To achieve clinical integration, future research must prioritize robust validation, interoperability with electronic health records, and transparent model interpretability. Bridging the gap between computational performance and real-world application could substantially improve outcomes and quality of life for LN patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.